Immunotherapy in renal cancer: present in the context of the past
Doc. MUDr. Jan Novotný, Ph.D.
Onkologi, Sunderby Sjukhus, Luieá, Švédsko
Metastatic renal carcinoma belongs to the class of malignancies in which an immunologic response is described, observed and used as a treatment strategy. In 2019, four randomized controlled trials studying four novel immunotherapy-based regimens have been published (nivolumab with ipilimumab, atezolizumab plus bevacizumab, avelumab plus axitinib and pembrolizumab with axitinib). Some of these regimens exert a survival advantage to the appropriately selected patients. All aspects of these studies are discussed in presented paper.
renal cancer, immunotherapy, PD-1 inhibitor, PD-L1 inhibitor, targeted therapy
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...